How to Interpret PTT (aPTT)
Interpret an isolated prolonged aPTT using a structured three-step approach: first verify the result and exclude pre-analytical errors and anticoagulants, then perform mixing studies with normal plasma to distinguish inhibitors from factor deficiencies, and finally proceed to specific confirmatory testing based on mixing study results.
Initial Assessment and Verification
When you encounter a prolonged aPTT, start by confirming the result is real and not artifactual 1:
- Verify specimen quality: Check for heparin contamination, underfilled tubes, clotted samples, or prolonged tourniquet time
- Review medication history: Identify patients on heparin, DOACs, or warfarin
- Confirm PT/INR is normal: An isolated aPTT prolongation (with normal PT) narrows your differential significantly 2, 3
Critical pitfall: DOACs and heparin are common causes of prolonged aPTT in clinical practice. Even sampling during the trough period of LMWH or DOACs may not eliminate their effect on testing 4.
Step 1: Mixing Studies
Once you've excluded pre-analytical issues and confirmed the prolongation, perform a 1:1 mixing study with normal pooled plasma 5:
Interpretation Framework
- Correction (normalized aPTT) → suggests factor deficiency
- Non-correction (persistent prolongation) → suggests inhibitor (lupus anticoagulant, specific factor inhibitor, or residual anticoagulant)
Use percentage correction as your primary calculation method for aPTT mixing studies 5. If the result indicates factor deficiency, confirm with subtraction III calculation (subtract the normal pooled plasma result from the mixing test result; correction indicated by result ≤0) 5.
Important Nuances
Borderline prolongations are particularly challenging 1. When mixing studies appear corrective but you remain uncertain:
- Escalate to enhanced mixing ratios (4:1 and 1:4 patient:normal plasma)
- Weak inhibitors or low-grade lupus anticoagulant activity can be masked by dilution in standard 1:1 mixing 1
Step 2: Directed Testing Based on Mixing Results
If Mixing Study Shows Correction (Factor Deficiency)
Proceed to specific factor assays focusing on intrinsic pathway factors:
- Factor VIII, IX, XI, XII deficiencies
- Less commonly: prekallikrein, high-molecular-weight kininogen
If Mixing Study Shows Non-Correction (Inhibitor Present)
Pursue lupus anticoagulant testing as the priority, as this is the most common cause 3:
The 2025 ISTH guidance mandates using two parallel tests: a dilute Russell's viper venom time (dRVVT) AND an LA-sensitive aPTT 4. Perform the corresponding test-specific mixing and confirmatory tests for any prolonged screening test to confirm phospholipid-dependent inhibition 4.
Critical evidence: Omitting either dRVVT or aPTT increases risk of underdiagnosis in up to 55% of triple antiphospholipid antibody-positive samples 4. This dual testing approach is non-negotiable for proper lupus anticoagulant detection.
Step 3: Special Considerations
Testing During Anticoagulation
Avoid testing for lupus anticoagulant during anticoagulation when possible 4. However, when unavoidable:
- Use DOAC removal agents for patients on direct oral anticoagulants
- Compare results pre- and post-DOAC removal to prevent misinterpretation
- Sample during trough periods for LMWH or DOACs as an alternative
- Document that complete DOAC removal cannot be guaranteed
Borderline Prolongations
For reproducible but mildly prolonged results just beyond the reference range 1:
- Verify analytical validity
- Apply quantitative correction indices (Rosner index, percent correction)
- If indeterminate, escalate to enhanced mixing ratios
- Perform factor assays with dilutional analysis including parallelism assessment
Clinical Context Matters
The three main causes of isolated prolonged aPTT are 3:
- Lupus anticoagulants (most common, paradoxically associated with thrombosis risk, not bleeding)
- Anticoagulant therapy (heparin, DOACs)
- Factor deficiencies (rare)
Do not assume bleeding risk from prolonged aPTT alone 2. Lupus anticoagulant causes aPTT prolongation but increases thrombotic risk, not bleeding risk. This distinction is critical for perioperative management and prevents unnecessary surgical delays.